CompletedPhase IInterventional

Phase I Trial: Quotient Code QSC302246

This early research study, known as QSC302246, is a 'Phase I' trial. This is a very early step in testing a potential new treatment in humans, usually to check its safety and how it works in the body. At this moment, we don't have many specific details about what this study is looking into or what the new treatment is. The organisation running the study has decided to keep these full details private for now, but they have promised to make them public within 30 months (two-and-a-half years) after the study officially ends. Only men are being asked to take part in this particular study, and there are no age limits mentioned. More information will be available later.

At a glance

Status

Completed

Phase

Phase I

Sponsor

Galen Limited

Enrolment target

Start

01 Dec 2025

Estimated completion

07 Jan 2026

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

What is this study about?

This is a 'Phase I' clinical trial, identified by the code QSC302246. Phase I trials are the very first time a new medicine or treatment is tested in people. Scientists and doctors use these early studies to see if the treatment is safe, to understand how it behaves in the human body, and to figure out what the right dose might be.

At this stage, the organisation running the study hasn't shared all the specific details about what exactly is being tested or why. Sometimes, companies keep this information private for a while, perhaps because they are developing something new and want to protect their research. However, they have committed to making all the full details public within 30 months – that's two and a half years – after the study has finished.

While we don't have the specific details yet, the overall goal of any Phase I trial is to gather initial information about a new treatment. This is a crucial step before it can move on to larger studies that test how well it works for specific health conditions. The information gathered here will help guide future research.

Key takeaways

This is a 'Phase I' trial, an early-stage study testing a new treatment.
Full details about the study are not yet public but will be shared later.
Information will be released within 30 months after the study finishes.
Only men can take part, with no age restrictions mentioned.
Taking part involves testing a brand new treatment in humans for the first time.

Who may be eligible?

Currently, we don't have specific details about exactly who can and cannot join this study. The organisers of the trial have chosen to keep these rules private for now.

However, we do know that only men are being asked to take part in this particular study. There are no age restrictions mentioned, meaning men of any age could potentially be considered.

The full details about who can be included in the study and who wouldn't be able to join will be made public within 30 months (two and a half years) after the study has officially ended. Once these details are available, you'll be able to see clearer guidelines.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you male?
Are you comfortable with details about the study being released at a later date?
Are you aware that this is an early-stage test of a new treatment?
Are you open to potentially unknown effects of a new treatment?

Answer every question to see your result.

What does participation involve?

Because all the details about this study are being kept private for now, we can't tell you exactly what taking part would involve. In a typical Phase I study, participants might need to visit a clinic regularly for health checks, blood tests, and to receive the new treatment. This could involve taking a medicine, or perhaps another type of treatment.

There would usually be a follow-up period after you've finished receiving the treatment to make sure you're doing well. The total time you would be involved in the study can vary a lot, from a few weeks to several months, but we don't have that information for this specific trial. Once the full details are released, you would get a clear picture of what's expected of you, including how many visits, what tests, and the overall duration.

Potential risks and benefits

Since the full details of this early-stage study are not yet public, we can't say what specific benefits or risks might be involved. In general, taking part in a Phase I trial might offer you early access to a new potential treatment before it's widely available. However, because these are very new treatments, there's always a chance of unknown side effects or that the treatment might not work as hoped. Participants in any clinical trial have the right to withdraw at any time, for any reason, without it affecting their usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Quotient Sciences Limited
City only
Nottingham, England

Common questions

What is a 'Phase I' trial?

A Phase I trial is the very first time a new medicine or treatment is tested in humans, usually to check if it's safe and how it works in the body.

Why aren't all the details available now?

The organisation running the study has chosen to keep some details private for now, perhaps to protect their research. They have promised to release all information later.

When will more details be shared?

All the full study details will be released within 30 months (two and a half years) after the study has officially ended.

Who can take part in this study?

Only men can take part. There are no specific age limits mentioned, so men of any age could potentially be considered.

Will I get access to a new treatment?

If you join, you would be involved in testing a new treatment. However, we don't have details on what that treatment is or what health conditions it aims to help yet.

How to find out more

David McCoubrey

regulatoryaffairs@almacgroup.com +44 (0)28 3833 4974 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.